
Experience
Abivax Announces $235.8 Million IPO
October 20, 2023
Cooley advised Abivax, a clinical-stage biotech company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, on its $235.8 million initial public offering.
Related contacts
Related Practices & Industries
Fontainebleau Aviation Signs Partnership Agreement With Skyservice
October 17, 2023
Cooley advised Fontainebleau Aviation, a part of Fontainebleau Development’s luxury services division, on its partnership with Skyservice Business Aviation.
Related contacts
Related Practices & Industries
Nuvolo Agrees to Sell to Trane Technologies
October 2, 2023
Cooley advised Nuvolo, a leader in modern, cloud-based connected workplace solutions, on its definitive agreement to be acquired by climate innovator Trane Technologies.
Related contacts
Related Practices & Industries
Rubicon Technology Partners Closes Strategic Investment in Tacton
August 1, 2023
Cooley advised private equity firm Rubicon Technology Partners on the strategic investment in Tacton, a top software as a service (SaaS) company trusted by global manufacturers.
Related contacts
Related Practices & Industries
Apogee Therapeutics Announces Upsized $345.1 Million IPO
July 18, 2023
Cooley advised the underwriters in the upsized $345.1 million initial public offering of Apogee Therapeutics, a biotechnology company.